Outlook Therapeutics Inc. (NASDAQ: OTLK) entered into an at-the-market offering agreement with H.C. Wainwright & Co. LLC on May 13, 2026, allowing the company to sell up to $100 million worth of common stock shares.

Under the sales agreement, H.C. Wainwright will serve as sales agent to sell shares from time to time through various methods, including direct sales on the Nasdaq Capital Market, other existing trading markets, or privately negotiated transactions at prevailing market prices.

The offering operates under the company's shelf registration statement on Form S-3, which the Securities and Exchange Commission declared effective on April 5, 2024. Outlook Therapeutics filed a prospectus supplement dated May 13, 2026, relating to the shares.

H.C. Wainwright will use commercially reasonable efforts to sell shares based on instructions from Outlook Therapeutics, including any price, time, size limits or other conditions the company may impose. The company is not obligated to sell any shares under the agreement.

Outlook Therapeutics will pay H.C. Wainwright a 3% commission on aggregate gross proceeds from any share sales. The company also agreed to reimburse certain legal expenses and fees incurred by H.C. Wainwright and provide customary indemnification rights.

Either party may terminate the sales agreement with five business days' prior written notice. The agreement includes standard representations, warranties and indemnification provisions.